On March 18, 2026, Chengdu kehonda Technology Co., Ltd. made a high-profile appearance at PCHi2026 (China International Personal Care and Homecare Ingredients Exhibition) held in Hangzhou. As a veteran enterprise deeply engaged in surfactant R&D and production for over 20 years, the company brought a full range of daily chemical core raw materials, including antibacterial and preservative agents, oil-control and anti-dandruff additives, antistatic agents, and emulsifying dispersants.
At the exhibition, we showcased our independently developed innovative raw material matrix, conducted in-depth technical exchanges and business negotiations with global downstream customers, industry partners and peers, and further expanded our layout in the global daily chemical and personal care market, highlighting our strong R&D strength and product competitiveness.
Hotspot mutations in isocitrate dehydrogenase 1 ( IDH1) and isocitrate dehydrogenase 2 ( IDH2) occur in a variety of myeloid malignancies and solid tumors. Mutant IDH proteins acquire a neomorphic enzyme activity to produce the putative oncometabolite D-2-hydroxyglutarate, which is thought to block cellular differentiation by competitively inhibiting α-ketoglutarate-dependent dioxygenases involved in histone and DNA demethylation. Small-molecule inhibitors of mutant IDH1 and IDH2 have been developed and are progressing through pre-clinical and clinical development. In this review, we provide an overview of mutant IDH-targeted therapy and discuss a number of important recent pre-clinical studies using models of IDH-mutant solid tumors.
